Underprovision and inequality of specialised cancer care
9 Sep 2017
Underprovision and inequality of specialised cancer care
Regorafenib versus lomustine for relapsed glioblastoma
Reviewing LORELEI, mindACT and ExteNET trials in breast cancer
Questioning the role of CT-scan in NSCLC post-surgery follow-up
Osimertinib suitable for first line EGFRm lung cancer
FLAURA study of osimertinib versus TKI for 1st line NSCLC
Follow-up on the IFCT-0302 trial
PACIFIC trial of durvalumab for lung cancer
ESMO 2017: CDK4/6 inhibitors from a patient’s perspective
Editor's Choice for August 2017
Introduction to iManageCancer apps - Italian translation
Introduction to iManageCancer apps - German translation